ACE and chronic kidney disease: Thus, the 2023 American Diabetes Association (ADA) guideline recommends the use of finerenone for individuals with T2D and CKD with albuminuria treated with the maximum tolerated doses of ACE inhibitors/ARB, to improve cardiovascular outcomes and reduce the risk of CKD progression (level of recommendation A) [64].